Abstract: High-risk low-grade gliomas (WHOⅡ grade) are a group of heterogeneous tumors originating from glial cells in the central nervous system. Surgery is usually the first choice of treatment, but the best postoperative treatment is still inconclusive. Studies have shown that postoperative radiotherapy and chemotherapy can improve the local control rate and overall survival time of some patients. However, there are still disputes about the best time for postoperative radiotherapy, the dose of radiotherapy, the choice of chemotherapeutic drugs, targeted therapy and immunotherapy for high-risk low-grade gliomas. This paper summarizes literatures at home and abroad, and discusses the current status and controversies of postoperative adjuvant therapy for high-risk low-grade gliomas.